Stock Market Today: Another Vaccine-Trial Stumble Clips Wall Street's Optimism
Johnson & Johnson (JNJ) paused a vaccine study, and Eli Lilly (LLY) was forced to do the same on a treatment trial, hampering stocks Tuesday.
Investors had plenty to chew on Tuesday, and it showed in a down day for stocks.
The big headline out of the gate was Johnson & Johnson (JNJ, -2.3%) pausing late-stage trials for its promising COVID-19 vaccine due to an "unexplained illness," which, as we explained when AstraZeneca (AZN) was forced to do the same, isn't uncommon and doesn't necessarily spell doom for the treatment.
"JNJ decided to temporarily halt all dosing of the Covid-19 vaccine candidate due to an unexplained illness in a volunteer in the study," writes CFRA's Sel Hardy, who nonetheless maintained a Strong Buy rating on JNJ and upgraded earnings estimates after the company's strong third-quarter earnings results. "We welcome JNJ's transparency and expect to see further clarity as the issue is examined by an independent board."
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Meanwhile, stimulus talks remained muddy; Senate Majority Leader Mitch McConnell said his chamber would vote on a bill centered around the Paycheck Protection Program (PPP) sometime this month, though it's uncertain whether it would get past the House.
Apple (AAPL, -2.7%) gave up a little of its recent gains after it unveiled a suite of four new iPhones, including an iPhone 12 Mini with a 5.4-inch screen. And JPMorgan Chase (JPM, -1.6%), which kicked off the Q3 earnings calendar by beating expectations, still slumped as CEO Jamie Dimon warned more stimulus is needed to help the economy.
The Dow Jones Industrial Average slipped 0.6% to 28,679.
Other action in the stock market today:
- The Nasdaq Composite managed a mere 0.1% decline to 11,863.
- The S&P 500 fell 0.6% to 3,511.
- The small-cap Russell 2000 lost 0.7% to 1,636.
COVID Treatments' Push and Pull on Wall Street
The broader market results don't indicate much fallout from today's disappointing COVID-19 news, which also included a halt to Eli Lilly's (LLY, -2.9%) antibody treatment.
But take a closer look: Industrials, real estate, banks and energy, which rely heavily on robust economic activity, were solidly lower today. However, technology and communications once again showed relative strength as they have all year, bolstering the fortunes of technology funds such as these 15 products, and that should continue to be the case as long as effective treatments and vaccines remain elusive.
The same goes for the Invesco QQQ Trust (QQQ), which invests in the index composed of the Nasdaq's 100 largest financials and has raked in billions in assets this year, prompting Invesco to launch even more funds tied to the index. (You can read about a host of Nasdaq-100 products here.)
At some point, however, a vaccine or treatment will finally get the green light, and while it might take months to reach most of America's population, most experts expect that to "flip the switch" for a host of battered industries. Here, we look at 11 stocks to buy that are in rough shape right now, but that could pivot in a heartbeat when a game-changing medical breakthrough is announced.
Disclaimer
Kyle Woodley was long AAPL and QQQ as of this writing.
Kyle Woodley is the Editor-in-Chief of WealthUp, a site dedicated to improving the personal finances and financial literacy of people of all ages. He also writes the weekly The Weekend Tea newsletter, which covers both news and analysis about spending, saving, investing, the economy and more.
Kyle was previously the Senior Investing Editor for Kiplinger.com, and the Managing Editor for InvestorPlace.com before that. His work has appeared in several outlets, including Yahoo! Finance, MSN Money, Barchart, The Globe & Mail and the Nasdaq. He also has appeared as a guest on Fox Business Network and Money Radio, among other shows and podcasts, and he has been quoted in several outlets, including MarketWatch, Vice and Univision. He is a proud graduate of The Ohio State University, where he earned a BA in journalism.
You can check out his thoughts on the markets (and more) at @KyleWoodley.
-
Stock Market Today: Nasdaq Soars on Strength in Magnificent 7 Stocks
The main indexes started the week strong after several mega-cap stocks rallied.
By Karee Venema Published
-
Target Limits Self-Checkout To 10 Items
Target launches new self-checkout lanes on heels of a new paid membership plan and expanded brand offerings.
By Jamie Feldman Published
-
Stock Market Today: Nasdaq Soars on Strength in Magnificent 7 Stocks
The main indexes started the week strong after several mega-cap stocks rallied.
By Karee Venema Published
-
Stock Market Today: Stocks Close Lower as Tech Shares Slump
Weakness in several Magnificent 7 stocks created headwinds for the main indexes Friday.
By Karee Venema Published
-
Stock Market Today: Stocks Swing Lower as Chipmakers Slump
The main indexes erased an early lead Thursday as several semiconductor stocks sold off.
By Karee Venema Published
-
Stock Market Today: Stocks End Mixed Ahead of Retail Sales, PPI
Stocks took a breather Wednesday as investors looked ahead to tomorrow's inflation data.
By Karee Venema Published
-
Stock Market Today: S&P 500 Nabs New Record Close After February CPI
Strong gains for Oracle and Nvidia helped the main indexes brush off hotter-than-anticipated inflation data.
By Karee Venema Published
-
Stock Market Today: Stocks Struggle Ahead of February CPI Report
The main indexes had trouble getting off the ground Monday as Wall Street waits for tomorrow's inflation update.
By Karee Venema Published
-
Where Can the Magnificent Seven Stocks Go in 2024?
The Magnificent Seven have been driving stock returns. Here, we take a close look at the mega-cap hotshots to see what's next.
By Nellie S. Huang Published
-
How To Avoid Capital Gains Taxes
A few small changes in your investing strategy can result in big tax advantages.
By Jeff Reeves Published